证券代码：603579 证券简称：荣泰健康 公告编号：2025-032 转 债代码：113606 转债简称：荣泰转债 上海荣泰健康科技股份有限公司 2024年年度股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 (一)股东大会召开的时间：2025 年 5 月 14 日 (二)股东大会召开的地点：上海市青浦区徐泾镇高光路 169 弄虹桥时代广场 6 号 楼荣泰大厦公司会议室 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 148 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 84,422,165 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | | | 份总数的比例（%） | 48.2155 | (四)表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 本次会议由公司董事会召集，公司董事长林光荣先生主持会议，会议 ...

| 证券代码：603579 | 证券简称：荣泰健康 | 公告编号：2025-031 | | --- | --- | --- | | 转债代码：113606 | 转债简称：荣泰转债 | | 上海荣泰健康科技股份有限公司 关于股东大会开设网络投票提示服务的公告 若广大投资者对本次服务有任何意见或建议，可通过邮件、投资者热线等方 式向公司反馈，感谢广大投资者对公司的关注与支持！ 公司邮箱：public@rotai.com 投资者热线电话：021-59833669 特此公告。 上海荣泰健康科技股份有限公司董事会 2025 年 5 月 14 日 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 上海荣泰健康科技股份有限公司（以下简称"公司"）拟于 2025 年 5 月 14 日 14:00 召开 2024 年年度股东大会，本次会议采用现场投票和网络投票相结合 的表决方式。具体内容详见公司分别在 2025 年 4 月 24 日、2025 年 5 月 9 日披 露于上海证券交易所的《关于召开 2024 年年度股东大会的通知》、《关于 2024 ...

Industry Overview - The massage chair industry combines traditional Chinese medicine techniques with modern technology, providing comfort and health benefits to users [1][4] - The market size of massage chairs in China is projected to grow from 6.191 billion yuan in 2019 to 8.485 billion yuan in 2024, indicating a robust development trend [1][10] - The sales volume of massage chairs is expected to increase from 1.2583 million units in 2019 to 1.5682 million units in 2024, reflecting a growing consumer demand [8][10] Market Environment - As of the end of 2024, the population aged 65 and above in China is projected to reach 220 million, accounting for 15.64% of the total population, driving demand for health-related products like massage chairs [6] - Over 70% of the population is in a sub-health state, with a significant portion being young adults, indicating a shift in the target demographic for massage chairs [6][8] - The increasing health awareness and changing consumption patterns among the middle class and young professionals are contributing to the stable growth of the massage chair market [8][10] Competitive Landscape - The massage chair market is characterized by intense competition between domestic and international brands, with leading domestic brands like OGAWA and Rongtai Health gaining market share [14][19] - The rise of e-commerce and shared economy models has led to the emergence of new players in the market, intensifying competition, especially in the mid-to-low-end segments [14][22] - The market is seeing a shift from traditional manufacturing to brand-driven strategies, enhancing brand value and consumer loyalty [14][19] Development Trends - The integration of smart technology and personalized services is becoming a key trend, with massage chairs utilizing AI and IoT to offer customized massage experiences [21][24] - The application scenarios for massage chairs are expanding beyond homes and offices to include public spaces like hotels and airports, enhancing consumer accessibility [22][23] - There is a growing trend towards integrating massage chairs with smart home systems, allowing for comprehensive health management solutions [24]

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：603579 证券简称：荣泰健康 公告编号：2025-030 转债代码：113606 转债简称：荣泰转债 上海荣泰健康科技股份有限公司 关于2024年年度股东大会取消部分议案的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 一、股东大会有关情况 1、股东大会的类型和届次 2024年年度股东大会 四、取消议案后股东大会的有关情况 （一）现场股东大会召开日期、时间和地点 召开日期时间：2025年5月14日 14点00分 召开地点：上海市青浦区徐泾镇高光路 169 弄虹桥时代广场 6 号楼荣泰大厦公司会议室 （二）网络投票的的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自2025年5月14日 2、股东大会召开日期： 2025年5月14日 3、股东大会股权登记日： ■ 二、取消议案的情况说明 1、取消议案名称 ■ 2、取消议案原因 至2025年5月14日 鉴于公司2025年员工持股计划草案相关事项尚需进一步沟通，公司基 ...

证券代码：603579 证券简称：荣泰健康 公告编号：2025-030 转债代码：113606 转债简称：荣泰转债 上海荣泰健康科技股份有限公司 关于2024年年度股东大会取消部分议案的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、 股东大会有关情况 1、 股东大会的类型和届次 2024年年度股东大会 2、 股东大会召开日期： 2025 年 5 月 14 日 3、 股东大会股权登记日： | 股份类别 | 股票代码 | 股票简称 | 股权登记日 | | --- | --- | --- | --- | | Ａ股 | 603579 | 荣泰健康 | 2025/5/8 | 二、 取消议案的情况说明 1、 取消议案名称 | 序号 | 议案名称 | | --- | --- | | 14 | 关于公司<2025 年员工持股计划（草案）>及其摘要的议案 | | 15 | 关于公司<2025 年员工持股计划管理办法>的议案 | | 16 | 关于提请股东大会授权董事会办理公司 年员工持股计 2025 | | | 划有关事项的议案 | ...

上海荣泰健康科技股份有限公司 2024 年年度股东大会 会议资料 中国·上海 二〇二五年五月 上海荣泰健康科技股份有限公司 2024 年年度股东大会会议资料 上海荣泰健康科技股份有限公司 2024 年年度股东大会会议议程 一、会议时间 现场会议：2025 年 5 月 14 日（星期三）14：00 网络投票：2025 年 5 月 14 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东大会召开当日的交易时间段，即 9:15-9:25，9:30-11:30，13:00-15:00；通过互 联网投票平台的投票时间为股东大会召开当日的 9:15-15:00。 涉及融资融券、转融通业务、约定购回业务相关账户以及沪股通投资者的投 票，应按照《上海证券交易所上市公司自律监管指引第 1 号 — 规范运作》等有 关规定执行。 二、现场会议地点 上海市青浦区徐泾镇高光路169弄虹桥时代广场6号楼荣泰大厦公司会议室 4、审议《关于公司 2024 年度财务报告的议案》 5、审议《关于公司 2024 年度财务决算报告的议案》 6、审议《关于公司 2024 年度利润分配预案的议案》 上海荣泰健康科技股份有限公司 ...

Group 1 - The A-share brain-computer interface sector experienced an initial rise, with Aipeng Medical increasing by over 8% [1] - Chengyitong, Rongtai Health, and Xiangyu Medical all saw increases of over 5% [1] - Companies such as Dineike and Sanbo Neuroscience also followed the upward trend [1]

Investment Rating - The investment rating for the company is "Buy" and is maintained [5] Core Viewpoints - The company experienced a temporary decline in performance, with a 13.92% year-on-year decrease in revenue for 2024, totaling 1.597 billion yuan. The net profit attributable to shareholders was 192 million yuan, down 5.31% year-on-year [2][9] - The company is actively expanding into new business areas, including automotive seating and AI-enabled products, to drive growth despite current market challenges [9] - The company has established strategic partnerships, including a collaboration with a leading global parts supplier and a joint project with Shanghai Jiao Tong University to develop an AI model for health applications [9] Financial Performance Summary - For 2024, the company reported total revenue of 1.597 billion yuan, a decrease of 13.92% year-on-year. The net profit attributable to shareholders was 192 million yuan, down 5.31% year-on-year, and the net profit after deducting non-recurring gains and losses was 163 million yuan, down 12.47% year-on-year [2][9] - In Q4 2024, the company achieved revenue of 433 million yuan, a decline of 22.34% year-on-year, with a net profit of 49 million yuan, down 3.02% year-on-year [2][9] - For Q1 2025, the company reported revenue of 395 million yuan, a slight decrease of 1.41% year-on-year, with a net profit of 44 million yuan, down 29.97% year-on-year [2][9] Product and Market Analysis - The company's revenue decline is attributed to weak market demand and intensified competition. Revenue from massage chairs and small massage appliances fell by 14.05% and 28.64% respectively, while experiential massage services saw a slight increase of 0.76% [9] - Domestic sales decreased by 20.17%, while international sales fell by 10.25%. The company is seeing varied performance across different international markets, with significant growth in its cross-border e-commerce business [9] Future Outlook - The company is expected to recover and achieve faster growth as market demand stabilizes. Projections for net profit attributable to shareholders for 2025, 2026, and 2027 are 172 million yuan, 194 million yuan, and 214 million yuan respectively, with corresponding price-to-earnings ratios of 23.81, 21.12, and 19.11 [9]

Core Viewpoint - Rongtai Health reported a decline in revenue and net profit for 2024, with a significant drop in Q4 and Q1 of 2025, while maintaining a high dividend payout ratio of 59.3% [1][4] Financial Performance - 2024 revenue, net profit attributable to shareholders, and net profit excluding non-recurring items were 1.6 billion, 190 million, and 160 million yuan, respectively, representing year-on-year declines of 14%, 5%, and 12% [1] - Q4 2024 figures were 430 million, 50 million, and 40 million yuan, with year-on-year declines of 22%, 3%, and 30% [1] - Q1 2025 figures were 390 million, 40 million, and 30 million yuan, with year-on-year changes of -1%, -30%, and -47% [1] Sales Performance - In 2024, revenue from massage chairs, small massage appliances, and experiential massage services were 1.52 billion, 50 million, and 5 million yuan, with year-on-year changes of -14%, -29%, and +0.8% [2] - Domestic and overseas market revenues in 2024 were 650 million and 920 million yuan, with year-on-year declines of 20% and 10% [2] - The overseas market showed mixed results, with declines in Korea and the US, while Europe and the Middle East saw stable growth [2] Profitability Metrics - Gross margin for 2024 and Q1 2025 were 31.7% and 32.5%, with year-on-year changes of +1.1 and -3.0 percentage points [3] - Expense ratios for sales, management, R&D, and financial expenses in 2024 were 11.3%, 5.4%, 5.0%, and -1%, with year-on-year changes of +0.5, +1.2, +0.7, and -0.2 percentage points [3] - Net profit margin for 2024, Q4 2024, and Q1 2025 were 12%, 11.4%, and 11.1%, with year-on-year changes of +1.1, +2.3, and -4.5 percentage points [3] Investment Outlook - The company is a leader in the domestic massage chair industry, focusing on channel reform and online content investment, with expected benefits from national subsidy policies in 2025 [4] - The company is expanding overseas and exploring new business areas such as automotive lightweight massage components and smart home devices [4] - The new employee stock ownership plan reflects long-term confidence in development, with projected net profits of 210 million and 240 million yuan for 2025 and 2026, corresponding to EPS of 1.2 and 1.3 yuan [4]

Investment Rating - The report maintains a "Buy" rating for the company, Rongtai Health (603579) [1][8] Core Views - The company has shown a recovery in gross margin in Q1 2025, with a focus on the DeepHealth smart health model, automotive scenarios, and new forms of robotic hands, indicating potential for growth [1][8] - The company reported a total revenue of 1.597 billion yuan in 2024, a decrease of 13.92%, and a net profit of 192 million yuan, down 5.31% [4][5] - The Q1 2025 revenue was 395 million yuan, a decline of 1.41%, with a net profit of 44 million yuan, down 29.97% [4][5] Summary by Sections Financial Performance - In 2024, the company's revenue from massage chairs and small massage appliances was 1.518 billion yuan and 51 million yuan, respectively, with year-on-year declines of 14.05% and 28.64% [5] - Domestic and overseas revenues in 2024 were 652 million yuan and 923 million yuan, respectively, with declines of 20.17% and 10.25% [5] - The gross margin improved from 29.66% in Q4 2024 to 32.54% in Q1 2025, an increase of 2.88 percentage points [6] - The net profit margin decreased from 11.33% in Q4 2024 to 11.14% in Q1 2025 [6] Product and Market Development - The company is expanding into automotive massage products and has established a subsidiary for this purpose, collaborating with Faurecia China [7] - A partnership with Shanghai Jiao Tong University aims to enhance product capabilities through AI [7] - The company anticipates growth in overseas markets, particularly in Europe and the Middle East, with a strong performance in cross-border e-commerce [5][7] Future Projections - The company expects net profits of 200 million yuan in 2025, 221 million yuan in 2026, and 246 million yuan in 2027, with corresponding EPS of 1.13, 1.25, and 1.39 yuan [8] - The projected revenue growth rates for 2025, 2026, and 2027 are 3.10%, 10.50%, and 10.70%, respectively [8]